Interpace Biosciences, Inc. (IDXG)
Stock Price:
$6.31 USD
0.00 (0.00%)
Updated Aug 5, 2020 4:00 PM EDT - Market open
After-hours: $6.12 -0.19 (-3.01%) Aug 5, 5:23 PM
Key Info
| Market Cap |
25.47M |
| Revenue (ttm) |
27.27M |
| Net Income (ttm) |
-41.67M |
| Shares Out |
4.04M |
| EPS (ttm) |
-9.32 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 5, 2020 |
| Last Price |
$6.31 |
| Previous Close |
$6.31 |
| Change ($) |
0.00 |
| Change (%) |
0.00% |
| Day's Open |
- |
| Day's Range |
6.12 - 6.44 |
| Day's Volume |
0 |
| 52-Week Range |
3.81 - 11.00 |
More Stats
| Market Cap |
25.47M |
| Enterprise Value |
14.68M |
| Earnings Date (est) |
Aug 18, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
4.04M |
| Float |
3.67M |
| EPS (basic) |
-8.57 |
| EPS (diluted) |
-9.32 |
| FCF / Share |
-5.80 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
117,101 |
| Short Ratio |
0.34 |
| Short % of Float |
4.63% |
| Beta |
1.70 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
0.93 |
| PB Ratio |
3.44 |
| Revenue |
27.27M |
| Operating Income |
-29.62M |
| Net Income |
-41.67M |
| Free Cash Flow |
-23.24M |
| Net Cash |
10.79M |
| Net Cash / Share |
2.67 |
| Gross Margin |
30.04% |
| Operating Margin |
-108.63% |
| Profit Margin |
-121.10% |
| FCF Margin |
-85.22% |
| ROA |
-25.19% |
| ROE |
-72.93% |
| ROIC |
-323.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$11.81*
(87.16% upside)
Low
9.25
Current: $6.31
High
14.00
Target: 11.81
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 24.08 | 21.90 | 15.90 | 13.09 | 9.43 | 1.47 | 147 | 127 | 157 | 135 |
| Revenue Growth | 9.97% | 37.74% | 21.49% | 38.73% | 539.89% | -98.99% | 15.47% | -19.32% | 16.87% | - |
| Gross Profit | 8.19 | 11.70 | 8.54 | 6.44 | 2.52 | 0.21 | 23.51 | 26.86 | 32.47 | 26.55 |
| Operating Income | -26.91 | -10.93 | -11.90 | -18.30 | -46.53 | -17.83 | -1.44 | -25.23 | -1.81 | -6.90 |
| Net Income | -27.16 | -12.19 | -12.22 | -8.33 | -11.36 | -16.07 | -4.57 | -25.53 | -11.91 | -6.81 |
| Shares Outstanding | 3.75 | 2.82 | 1.58 | 0.18 | 0.15 | 0.15 | 0.15 | 0.15 | 0.14 | 0.14 |
| Earnings Per Share | -7.25 | -4.33 | -7.70 | -45.90 | -73.40 | -108.00 | -31.00 | -175.00 | -83.00 | -48.00 |
| Operating Cash Flow | -18.96 | -8.67 | -15.26 | -7.61 | -19.84 | -16.38 | -3.51 | -10.29 | 1.99 | 16.35 |
| Capital Expenditures | -0.12 | -0.45 | -0.03 | - | -0.35 | -2.85 | -1.82 | -1.11 | -0.34 | -2.13 |
| Free Cash Flow | -19.08 | -9.12 | -15.29 | -7.61 | -20.20 | -19.23 | -5.33 | -11.40 | 1.64 | 14.22 |
| Cash & Equivalents | 2.32 | 6.07 | 15.20 | 0.60 | 8.42 | 23.22 | 45.74 | 52.88 | 64.46 | 62.86 |
| Total Debt | 5.59 | - | - | 7.91 | 8.40 | 27.15 | - | - | - | - |
| Net Cash / Debt | -3.27 | 6.07 | 15.20 | -7.31 | 0.02 | -3.94 | 45.74 | 52.88 | 64.46 | 62.86 |
| Assets | 69.05 | 48.44 | 53.60 | 41.78 | 67.71 | 116 | 69.06 | 78.45 | 113 | 124 |
| Liabilities | 29.85 | 15.50 | 13.73 | 35.25 | 54.67 | 95.78 | 36.59 | 42.82 | 53.86 | 54.88 |
| Book Value | 13.03 | 32.94 | 39.87 | 6.53 | 13.04 | 20.12 | 32.48 | 35.63 | 59.52 | 69.51 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Interpace Biosciences, Inc. |
| Country |
United States |
| Employees |
176 |
| CEO |
Jack E. Stover |
Stock Information
| Ticker Symbol |
IDXG |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Diagnostics & Research |
| Unique Identifier |
NASDAQ: IDXG |
| IPO Date |
May 20, 1998 |
Description
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.